TMCnet News
ACAD, COSI, RGEN, PSTI, PJC, DSX Are Seasonally Ripe To Go Down In the Next Five WeeksNov 12, 2012 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), Cosi Inc (NASDAQ:COSI), Repligen Corp (NASDAQ:RGEN), Pluristem Therapeutics Inc (NASDAQ:PSTI), Piper Jaffray Companies (NYSE:PJC), Diana Shipping Inc (NYSE:DSX) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php The following stocks are expected to go Down: Symbol Company Expected Return Odds By The Following Date ACAD ACADIA Pharmaceuticals Inc -10.64% 87.50% (7 of 8) Monday, November 26th 2012 COSI Cosi Inc -11.10% 88.89% (8 of 9) Monday, December 10th 2012 RGEN Repligen Corp -5.46% 91.67% (11 of 12) Thursday, November 22nd 2012 PSTI Pluristem Therapeutics Inc -11.61% 88.89% (8 of 9) Tuesday, November 20th 2012 PJC Piper Jaffray Companies -6.06% 87.50% (7 of 8) Tuesday, November 27th 2012 DSX Diana Shipping Inc -7.01% 100.00% (7 of 7) Friday, December 7th 2012 ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development in collaboration with Meiji Seika Kaisha, Ltd. In addition, ACADIA Pharmaceuticals Inc. is developing two preclinical programs in the area of Parkinsons disease. The product candidates in the companys pipeline emanate from discoveries made using its proprietary drug discovery platform. The company was founded in 1993 and is headquartered in San Diego, California.. Cosi Inc (NASDAQ:COSI) - Cosi, Inc. owns, operates, and franchises premium convenience dining restaurants. The company offers squagels, sandwiches, bagels, salads, soups, appetizers, melts, flatbread pizzas, Smores, and other desserts; coffees and other espresso-based beverages, seasonal fruit smoothies and specialty drinks, soft drinks, flavored teas, and bottled beverages, such as still and sparkling waters; and alcoholic beverages, which include beer and wine. Its restaurants also provide catering services for the breakfast and lunch day parts. As of May 13, 2010, the company had 86 Company-owned and 57 franchise restaurants operating in 18 states, the District of Columbia, and the United Arab Emirates. Cosi, Inc. was founded in 1994 and is based in Deerfield, Illinois.. Repligen Corp (NASDAQ:RGEN) - Repligen Corporation, a biopharmaceutical company, engages in the development and commercialization of therapies that deliver value to patients and clinicians in neurology, gastroenterology, and orphan diseases. It sells a line of commercial bioprocessing products based on Protein A, as well as single or limited campaign use pre-packed chromatography columns, which are used in the production of monoclonal antibodies and other biopharmaceutical manufacturing applications. The company also offers intellectual property on monoclonal antibody and antibody fusion products consisting of CTLA4, a regulator of the activity of the immune system that provides a treatment for patients who are refractory to existing therapies, as well as certain autoimmune disorders, including rheumatoid arthritis; and Erbitux, a monoclonal antibody for the treatment of certain forms of colon cancer, as well as head and neck cancer. In addition, its development stage products include Secretin for MRI imaging of the pancreas; Uridine for bipolar depression; Histone Deacetylase Inhibitors for Friedreichs Ataxia; and DcpS Inhibitors for spinal muscular atrophy. Further, the company involves in the development and commercialization of products that are used for the production of biopharmaceuticals. It sells its products through value added resellers, as well as through distributors. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.. Pluristem Therapeutics Inc (NASDAQ:PSTI) - Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the companys proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The companys principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.. Piper Jaffray Companies (NYSE:PJC) - Piper Jaffray Companies provides investment banking services, institutional sales, trading and research services, and asset management services worldwide. The company primarily raises capital through equity financings for its middle-market clients operating in various industries, including the business services; clean technology and renewables; consumer; financial institutions; healthcare; industrial growth; and media, telecommunications, and technology. It offers financial advisory services relating to mergers and acquisitions; underwrites debt issuances; and provides financial advisory and interest rate risk management services. The companys public finance investment banking capabilities focus on state and local governments, healthcare, higher education, housing, hospitality, transportation, and commercial real estate industries. Piper Jaffray Companies also offers equity and fixed income advisory and trade execution services for institutional investors, public and private corporations, public entities, and non-profit clients; has equity sales and trading relationships with institutional investors in the United States, Asia, and Europe; and engages in proprietary trading. In addition, it provides asset management services to separately managed accounts, partnerships, and open and closed-end mutual funds; offers an array of investment products comprising small and mid-cap value equity, master limited partnerships focused on the energy industry, as well as fixed income; and invests in private equity and venture capital funds. The company was founded in 1895 and is headquartered in Minneapolis, Minnesota.. Diana Shipping Inc (NYSE:DSX) - Diana Shipping Inc. provides shipping transportation services worldwide. The company transports dry bulk cargoes that include commodities, such as iron ore, coal, grain, and other materials along worldwide shipping routes. As of December 31, 2009, its fleet consisted of 13 Panamax dry bulk carriers and 7 Capesize dry bulk carriers that had a combined carrying capacity of approximately 2.2 million deadweight tonnage. Its customers include national, regional, and international companies. The company was formerly known as Diana Shipping Investments Corp. and changed its name to Diana Shipping Inc. in February 2005. Diana Shipping Inc. was founded in 1999 and is based in Athens, Greece.. SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include: REGULATORY & COMPLIANCE NEWS Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements". RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO. INVESTMENTS & TRADING SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports. Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks. Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups. Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks. GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time. About SQUEEZETRIGGER.COM WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades. SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin. All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind. Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC. Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 [email protected] SqueezeTrigger is a registered trademark, Reg. No. 3,120,641 CONTACT: Buyins.net Thomas Ronk [email protected] www.buyins.net ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. |